MedTrace Logo

Inhaled Heparin for Hospitalised Patients With Coronavirus Disease 2019 (COVID-19)

NCT05184101 · Status: WITHDRAWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL

Last updated 2024-02-26

No results posted yet for this study

Summary

Investigator-initiated, multi-centre, randomised, open-label trial of nebulised heparin sodium in addition to standard care compared to standard care alone in hospitalised patients with COVID-19 infection.

Conditions

Interventions

DRUG

Unfractionated Heparin

Heparin sodium will be administered as a nebulised aerosol dose of 25,000 IU heparin three times a day (TDS) via an Aerogen Solo (Aerogen, Ireland) vibrating mesh aerosol drug nebulizer.

Sponsors & Collaborators

  • The George Institute

    collaborator OTHER

  • St George Hospital, Australia

    collaborator OTHER

  • St Vincent's Hospital Melbourne

    collaborator OTHER

  • John Hunter Hospital

    collaborator OTHER_GOV

  • Royal North Shore Hospital

    collaborator OTHER

  • Australian National University

    lead OTHER

Principal Investigators

  • Frank MP van Haren, PhD · Australian National University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-31
Primary Completion
2023-12-01
Completion
2024-03-01

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05184101 on ClinicalTrials.gov